M-A: Sodium-glucose Cotransporter 2 inhibitors are associated with reduced risk of hyperkalemia in people with type 2 diabetes. 13 Apr, 2022 | 10:52h | UTC Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials – Circulation